These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28952016)

  • 1. The impact of irreproducibility and competing protection from P2Y
    Cohen MV; Downey JM
    Basic Res Cardiol; 2017 Sep; 112(6):64. PubMed ID: 28952016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered.
    Cohen MV; Downey JM
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):179-90. PubMed ID: 24298192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial Despair and Current Hope of Identifying a Clinically Useful Treatment of Myocardial Reperfusion Injury: Insights Derived from Studies of Platelet P2Y
    Cohen MV; Downey JM
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cangrelor-Mediated Cardioprotection Requires Platelets and Sphingosine Phosphorylation.
    Cohen MV; Yang XM; White J; Yellon DM; Bell RM; Downey JM
    Cardiovasc Drugs Ther; 2016 Apr; 30(2):229-32. PubMed ID: 26780906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts.
    Yang XM; Liu Y; Cui L; Yang X; Liu Y; Tandon N; Kambayashi J; Downey JM; Cohen MV
    Cardiovasc Drugs Ther; 2013 Apr; 27(2):109-15. PubMed ID: 23318690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical Issues for the Translation of Cardioprotection.
    Heusch G
    Circ Res; 2017 Apr; 120(9):1477-1486. PubMed ID: 28450365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Realizing the clinical potential of ischemic preconditioning and postconditioning.
    Yellon DM; Hausenloy DJ
    Nat Clin Pract Cardiovasc Med; 2005 Nov; 2(11):568-75. PubMed ID: 16258568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is Wrong With Cardiac Conditioning? We May be Shooting at Moving Targets.
    Iliodromitis EK; Cohen MV; Dagres N; Andreadou I; Kremastinos DT; Downey JM
    J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):357-69. PubMed ID: 25627214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is it time to translate ischemic preconditioning's mechanism of cardioprotection into clinical practice?
    Cohen MV; Downey JM
    J Cardiovasc Pharmacol Ther; 2011; 16(3-4):273-80. PubMed ID: 21821528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P2Y12 inhibitors adjunctive to primary PCI therapy in STEMI: fighting against the activated platelets.
    Alexopoulos D
    Int J Cardiol; 2013 Mar; 163(3):249-255. PubMed ID: 22192279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
    Ferdinandy P; Schulz R; Baxter GF
    Pharmacol Rev; 2007 Dec; 59(4):418-58. PubMed ID: 18048761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Affecting Platelet Reactivity 2 Hours After P2Y₁₂ Receptor Antagonist Loading in Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction - Impact of Pain-to-Loading Time.
    Xanthopoulou I; Davlouros P; Tsigkas G; Koutsogiannis N; Patsilinakos S; Deftereos S; Hahalis G; Alexopoulos D
    Circ J; 2016; 80(2):442-9. PubMed ID: 26597388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signalling pathways and mechanisms of protection in pre- and postconditioning: historical perspective and lessons for the future.
    Cohen MV; Downey JM
    Br J Pharmacol; 2015 Apr; 172(8):1913-32. PubMed ID: 25205071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of a P2Y
    Amann M; Ferenc M; Valina CM; Bömicke T; Stratz C; Leggewie S; Trenk D; Neumann FJ; Hochholzer W
    Platelets; 2016 Nov; 27(7):668-672. PubMed ID: 27065056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotection in the clinical setting.
    Ivanes F; Mewton N; Rioufol G; Piot C; Elbaz M; Revel D; Croisille P; Ovize M
    Cardiovasc Drugs Ther; 2010 Jun; 24(3):281-7. PubMed ID: 20589423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel cardioprotective and regenerative therapies in acute myocardial infarction: a review of recent and ongoing clinical trials.
    Spath NB; Mills NL; Cruden NL
    Future Cardiol; 2016 Nov; 12(6):655-672. PubMed ID: 27791385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction.
    Ye Y; Birnbaum GD; Perez-Polo JR; Nanhwan MK; Nylander S; Birnbaum Y
    Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1805-14. PubMed ID: 26044583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical effects and outcomes with new P2Y12 inhibitors in ACS.
    Collet JP; O'Connor S
    Fundam Clin Pharmacol; 2012 Feb; 26(1):16-8. PubMed ID: 21895760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in platelet blockers: the target is the P2Y12 receptor.
    Patel PA; Lane B; Augoustides JG
    J Cardiothorac Vasc Anesth; 2013 Jun; 27(3):620-4. PubMed ID: 23672863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.